The content is available as a PDF (338.6 KB).
References
- 1.Bhat CS, Gupta L, Balasubramanian S, Singh S, Ramanan AV. Hyperinflammatory syndrome in children associated with COVID-19: Need for awareness. Indian Pediatr. 2020;57:929–35. doi: 10.1007/s13312-020-1997-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Fouriki A, Fougère Y, De Camaret C, et al. Case series of children with multisystem inflammatory syndrome following SARS-CoV-2 infection in Switzerland. Front Pediatr. 2021;8:594127. doi: 10.3389/fped.2020.594127. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Harwood R, Allin B, Jones CE, et al. PIMS-TS National Consensus Management Study Group. A National Consensus Management Pathway For Paediatric Inflammatory Multisystem Syndrome Temporally Associated With COVID-19 (PIMS-TS): Results of a National Delphi Process. Lancet Child Adolesc Health. 2021;5:133–41. doi: 10.1016/S2352-4642(20)30304-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Henderson LA, Canna SW, Friedman KG, et al. American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 2. Arthritis Rheumatol. 2021;73:e13–e29. doi: 10.1002/art.41616. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Nuffield Department of Population Health. Information for site staff 2020. Accessed June 21, 2021. Available from: https://www.recoverytrial.net/for-site-staff
- 6.Shakoory B, Carcillo JA, Chatham WW, et al. Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of the macrophage activation syndrome: Re-analysis of a prior phase III trial. Crit Care Med. 2016;44:275–28. doi: 10.1097/CCM.0000000000001402. [DOI] [PMC free article] [PubMed] [Google Scholar]